Advertisement

Ciclopirox Nail Lacquer 8% for the Treatment of Onychomycosis: A Canadian Perspective

Onychomycosis is prevalent, and risk factors, such as old age and diabetes, are increasing. This condition has been treated using oral antifungal agents with varying degrees of success. Recently, ciclopirox nail lacquer 8% solution became the first topical agent approved in Canada for onychomycosis.

New Approaches to Surgery of Lentigo Maligna

Lentigo maligna (LM) is a pigmented lesion that occurs most commonly on the sun-exposed skin of the head and neck of an older patient. LM can be difficult to completely remove due to its occasional extensive subclinical extension. The gold standard treatment for LM is margin-controlled excision.

Fixed Combination Halobetasol Propionate and Tazarotene Lotion for Plaque Psoriasis

A novel fixed combination lotion containing the super-potent corticosteroid halobetasol propionate 0.01% and retinoid tazarotene 0.045% (Duobrii™) has recently been introduced and indicated for the treatment of moderate to severe plaque psoriasis in adults.

Novel Flaps for Lip Reconstruction

Reconstruction of the lips requires careful attention to aesthetic and functional goals. We describe our approach to lip repair and present novel methods to maintain symmetry and function, and optimize cosmetic results.

Moxifloxacin (Avelox®) For The Treatment Of Bacterial Skin Infections

Moxifloxacin (Avelox®, Bayer), which is available for oral administration, is a broad-spectrum synthetic antimicrobial agent with excellent Gram-positive activity and good Gram-negative activity. The US FDA recently approved this drug for the treatment of bacterial skin infections.

Update on Drugs and Drug News: May 2002

Update on: Alefacept AMEVIVE®Sodium Hyaluronate LAM IPM Wound Gel® Hydroquinone, Tretinoin, Fluocinolone Acetonide Tri-Luma® Cream Loratidine Claritin®

Update on Drugs and Drug News: May 2001

Update on: Moxifloxacin HCl Avelox Recombinant Human Iduronidase (IDUA) Neurotoxins Botox Graftskin Apligraf

Skin, Hair and Nail Supplements: An Evidence-Based Approach

Dermatology supplements, often marketed as “skin, hair, and nail” supplements, are becoming increasingly popular. However, many consumers lack an understanding of the science of dietary supplements or the specifics of the supplement industry.

Update on Drugs and Drug News – April 2008

Update on Peginterferon alfa-2b PEG-Intron™, Elesclomol (formerly STA-4783), Hyaluronic Acid Gel + Lidocaine Prevelle Silk™.

Update on Drugs and Drug News: November-December 2016

Update on drugs, approval dates, and comments. Brodalumab for SC injection (Lumicef®), Etanercept-szzs for SC injection (Amjevita™), Propranolol hydrochloride oral solution 3.75 mg/ml (Hemangiol®), Calcipotriol 50 mcg/g + betamethasone dipropionate 0.5 mg/g foam (Enstilar®) are covered.

Update on Drugs and Drug News: January-February 2017

Update on drugs, approval dates, and comments for Nivolumab + ipilimumab (Opdivo® + Yervoy®), Etanercept for SC injection (Enbre®), Crisaborole 2% ointment (Eucrisa™ ), Hyaluronic acid dermal fillers Restylane® (Refyne Restylane® Defyne).

Hair Removal Practices: A Literature Review

This article is a general overview of hair removal practices, which have evolved from utilizing waxes and blades, to advanced lasers and electrolysis, with further advancements still being studied

Acne Scars: An Update on Management

Acne scars are a frequent complication that results from damage to the skin during the healing process of lesions, with studies indicating that 50% of those suffering from acne may develop scars.

Update on Drugs and Drug News: January, 1998

Update on: Norgestimate / Ethinylestradiol Tri-Cyclen® Lidocaine/Prilocaine Cream Emla®Tretinoin gel 0.025% Avita® Adapalene solution 0.1% Differin®Topical tissue adhesive Dermabond® Atorvastin calcium Lipitor® Isotretinoin Accutane®

Update on Drugs and Drug News: January 2002

Update on: Pimecrolimus Elidel®Butenafine HCl 1% Cream Lotrimin Ultra®Doxycycline Vibramycin®Fluocinolone acetonide Derma-Smoothe/FS®Doxycycline Thalidomid®

Psychosocial Impact of Acne Vulgaris: Evaluating the Evidence

This paper reviews current evidence presented by recent studies on the impact of acne on psychosocial health. Effective treatment of acne was accompanied by improvement in self-esteem, affect, obsessive-compulsiveness, shame, embarrassment, body image, social assertiveness and self-confidence.

Immunological Strategies to Fight Skin Cancer

Skin cancer is the most common human cancer, and is currently considered a global epidemic. Recently, there has been a growing interest in immunomodulators, or upregulators of the immune response.

Frontal Fibrosing Alopecia

Frontal fibrosing alopecia has become one of the most frequently seen causes of scarring alopecia at many specialist hair clinics. It has distinctive features and associations which distinguish it from LPP. Discussion includes familial or genetic factors, etiology, and trials.

Afamelanotide in the Treatment of Dermatologic Disease

Afamelanotide, an α-melanocyte stimulating hormone analogue, has become an emerging therapeutic option for a variety of skin conditions previously refractory to other treatments.

Update on Drugs & Devices: November – December 2020

This update covers: Gene therapy for DEB (AGLE-102), Golimumab for IV use (Simponi® Aria™), Clascoterone 1% cream (Winlevi®), Triplet melanoma therapy (Tecentriq® + Cotellic® and Zelboraf®), Ustekinumab for SC use (Stelara®), Calcipotriene + betamethasone dipropionate cream (Wynzora®), Abametapir 0.74% lotion (Xeglyze™), Sonidegib capsules (Odomzo®) and Halobetasol propionate + tazarotene lotion (Duobrii™).

A Review of Systemic Retinoid Therapy for Acne and Related Conditions

Oral isotretinoin, since its introduction more than 20 years ago, has been and still is the 'gold standard' in the treatment of acne and its variants. This is the only approach to acne with the possibility of a permanent “cure” or long term remission.

Topical 3% Diclofenac in 2.5% Hyaluronan Gel for the Treatment of Actinic Keratoses

Many of the treatment options available can cause discomfort, pain or skin irritation. Topical 3% diclofenac in 2.5% hyaluronan gel (Solaraze™, Bioglan Pharma) is a relatively new treatment that has been shown to be effective and well tolerated for the treatment of AKs.

Update on Drugs and Drug News: March 2011

Update on drugs, approval dates, and comments. Spinosad 0.9% cream rinse (Natroba™), Light emitting diode (LED) skin rejuvenation system (Tanda™ Professional Rejuvenate), Voclosporin Voclera™ (ISA247) are covered.

Polycystic Ovary Syndrome and Acne

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive aged women. This article will review the treatments for acne due to androgen excess in PCOS women.

Oral Lichen Planus: Treatment Options

Estimates of the percentage of patients with cutaneous lichen planus (LP) who also have oral LP vary from somewhere between a third and a half 1-3, to as high as 70% and even higher when the cutaneous lesions are of long duration.

Update on Drugs and Drug News: September-October 2015

Update on Nivolumab IV infusion (Opdivo®), Pembrolizumab IV infusion (Keytruda®), Sonidegib phosphate capsules (Odomzo®), Azelaic acid 15% foam (Finacea® Foam), Adapalene 0.3% + benzoyl peroxide 2.5% gel (Epiduo® Forte), Deoxycholic acid injection (Belkyra™), Hyaluronic acid gel injectable dermal filler (Restylane® Lyft with Lidocaine), Dermal filler with calcium hydroxylapatite (CaHA) + integral 0.3% lidocaine (Radiesse® (+)

Calcipotriol and Betamethasone Dipropionate (Dovobet®, Daivobet®): A New Formulation for the Treatment of Psoriasis

A new compound product containing calcipotriol 50μg/gm and betamethasone dipropionate 0.5mg/gm (Dovobet*, LEO Pharma) in an ointment base was recently introduced in Canada for the treatment of psoriasis.

Update on Drugs & Devices: May – June 2020

Update on Selumetinib capsules (Koselugo®), Crisaborole 2% ointment (Eucrisa®), Infliximab biosimilar for IV injection (Avsola™) and Baricitinib tablets (Olumiant®)

Drug Treatments for Skin Disease Introduced in 2001

An overview and update of skin conditions and treatments introduced in 2001: Quick overview of drug name, indications and regulatory status

Ingenol Mebutate: An Introduction

The incidence of nonmelanoma skin cancer continues to increase. This article discusses ingenol mebutate, its history, mechanism of action, and recent trial evidence for this emerging therapy are discussed.

Squamous Cell Carcinoma in Organ Transplant Recipients: Approach to Management

Skin cancer, particularly squamous cell carcinoma (SCC), continues to be a significant cause of morbidity and even mortality in organ transplant recipients (OTRs). As the number of organ transplant patients continues to increase, dermatologists will be faced with the challenge of diagnosing and managing their skin cancers.

A Review of Biologic Treatments for Psoriasis with Emphasis on Infliximab

Moderate-to-severe psoriasis is known to affect millions of people around the globe. This chronic disease substantially impacts patients by impairing their quality of life. The biologics are the newest and most effective therapeutic weapon in the treatment of moderate-to-severe psoriasis and psoriatic arthritis.

Current Concepts in Laser Tattoo Removal

Today, more than 10% of the Western population has at least 1 tattoo, with prevalence of up to one-fourth in the cohort younger than 30 years of age. This article provides an overview of applicable laser systems and therapeutic strategies for optimized tattoo removal.

Update on Drugs and Drug News: April 2002

Update on drugs: Fluocinolone Acetonide, Hydroquinone, Tretinoin Tri-Luma®Pimecrolimus Elidel®Clindamycin, Zinc Zindaclin™ Gel Voriconazole Vfend® Imiquimod Aldara® 5% Cream

Update on Drugs and Drug News: March, 2000

Update on: Tissue Engineered Collagen Matrix Oasis Wound Dressing Bexarotene Targretin Gel 1% Eflornithine Hydrochloride Vaniqa Cream 15% Biologically Active Dressing Composite Cultured Skin (CCS) Famciclovir Famvir Moxifloxacin Avelox/Avalox Finasteride 1mg Tablets Propecia

Antibiotic Resistance in Acne Treatment

Propionibacterium acnes (P. acnes) is an anaerobic bacteria implicated in the pathogenesis of acne. Current treatment guidelines offer strategies to limit the potential for resistance while achieving optimal outcome in the management of inflammatory and non-inflammatory acne.

Drug Treatments for Skin Disease Introduced in 2006

An overview and update of skin conditions and treatments introduced in 2006: Quick overview of drug name, indications and regulatory status

Update on Drugs and Drug News – May 2007

Update on Antiacne Agent Drospirenone/ Ethinyl Estradiol Yaz® Berlex, Corticosteroid Clobetasol Propionate 0.05% Olux-E™ Foam Stiefel Laboratories and news from US FDA.

Topical Tacrolimus

Currently, tacrolimus is emerging as a promising therapeutic alternative for the treatment of a number of dermatological diseases that have in common an aberrant immunologic response. This topical ointment is the first of its kind to be approved by the US FDA (December 2000), 0.1% for the treatment of moderate-to-severe atopic dermatitis in adults, and 0.03% for children older than 2 years of age and for adults who are undergoing long-term intermittent therapy.

Update on Drugs & Devices: November – December 2018

Update on PrabotulinumtoxinA, Tretinoin 0.05% lotion, Cemiplimab-rwlc, Autologous fibroblast gene therapy, Oral JAK3 inhibitor, Halobetasol propionate 0.01% lotion, Sarecycline hydrochloride tablets and HPV 9-valent vaccine.

POPULAR

Advertisement